Blood type study in newly diagnosed leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks at blood types (ABO and Rh) in people newly diagnosed with acute leukemia. It may help doctors understand if certain blood types are more common in these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acute leukemia (ALL or AML) for the first time.
- Your diagnosis must have happened between 2022 and 2025.
- Your medical records must include your ABO and Rh blood type.
- You must be a patient at South Egypt Cancer Institute, Assiut University.
- You cannot have other cancers or long-term serious illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at simple blood test results from people newly diagnosed with acute lymphoblastic leukemia (ALL) to see if certain markers help understand the disease better.
This study measures two simple blood markers (SII and CAR) in people newly diagnosed with acute lymphoblastic leukemia (ALL) who haven't started treatment yet. The goal is to see if these markers can help guide care.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
This study is for adults with acute myeloid leukemia (AML) whose cancer has returned or is not responding to treatment. Researchers will analyze your leukemia cells to learn more about the disease and possibly find better treatments.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.